NasdaqGM - Delayed Quote • USD
Galera Therapeutics, Inc. (GRTX)
At close: 4:00 PM EDT
After hours: 4:03 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.58 | -0.5 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.54 | -0.38 | -0.38 | -0.4 |
| EPS Actual | -0.58 | -0.5 | -0.48 | -0.28 |
| Difference | -0.04 | -0.12 | -0.1 | 0.12 |
| Surprise % | -7.40% | -31.60% | -26.30% | 30.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.35 | -0.32 | -1.76 | -1.24 |
| 30 Days Ago | -0.35 | -0.32 | -1.76 | -1.24 |
| 60 Days Ago | -0.35 | -0.32 | -1.76 | -1.24 |
| 90 Days Ago | -0.35 | -0.32 | -1.76 | -1.24 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GRTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 6.50% |
| Next Qtr. | -- | -- | -- | 12.00% |
| Current Year | -- | -- | -- | 5.30% |
| Next Year | -- | -- | -- | 13.10% |
| Next 5 Years (per annum) | 34.40% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Citigroup: Neutral to Neutral | 8/29/2023 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 8/16/2023 |
| Downgrade | Piper Sandler: Overweight to Neutral | 8/10/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/17/2023 |
| Maintains | HC Wainwright & Co.: Buy | 3/22/2023 |
| Initiated | Piper Sandler: Overweight | 2/21/2023 |
Related Tickers
THAR Tharimmune, Inc.
0.3691
+2.50%
PIRS Pieris Pharmaceuticals, Inc.
11.72
+1.03%
SPRB Spruce Biosciences, Inc.
0.7000
-0.14%
EIGRQ Eiger BioPharmaceuticals, Inc.
2.5000
-17.76%
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
ALVR AlloVir, Inc.
0.7971
-0.36%
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
NXTC NextCure, Inc.
1.3500
+4.65%
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%